Structure Therapeutics Reports Positive Oral Weight-Loss Data
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
Amylin
Advertisement
Ascletis Joins Hong Kong Stock Connect Programs
Hong Kong, September 7, 2026 Ascletis Pharma Inc. has announced that its ordinary shares have been included as eligible...
Specialised Therapeutics Expands Minjuvi Access in Australia
Singapore, August 2, 2026 Specialised Therapeutics (ST) announced that Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been...
GlycoNex Doses First Patient in Phase I Trial of GNX1021
Taipei, August 3, 2026 GlycoNex Inc. announced that the first patient has been successfully dosed in the first-in-human Phase...
AusperBio Doses First Patient for AHB-171 HBV Clinical Study
San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...
Advertisements
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Advertisement
